Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Fresenius Medical Care Corporation is a medical care facilities business based in the US. Fresenius Medical Care Corporation shares (FMS) are listed on the NYSE and all prices are listed in US Dollars. Fresenius Medical Care Corporation employs 122,635 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $25.11 |
|---|---|
| 52-week range | $23.29 - $41.12 |
| 50-day moving average | $28.80 |
| 200-day moving average | $32.08 |
| Wall St. target price | $31.59 |
| PE ratio | 15.7925 |
| Dividend yield | $1.35 (2.82%) |
| Earnings per share (TTM) | $1.59 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $25.11 from 2022-07-01
| 1 week (2022-06-23) | 3.89% |
|---|---|
| 1 month (2022-05-31) | -17.70% |
| 3 months (2022-03-31) | N/A |
| 6 months (2022-01-04) | -22.69% |
| 1 year (2021-07-02) | -38.64% |
|---|---|
| 2 years (2020-07-02) | -43.29% |
| 3 years (2019-07-03) | 39.85 |
| 5 years (2017-07-03) | 48.19 |
Valuing Fresenius Medical Care Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Fresenius Medical Care Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Fresenius Medical Care Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 16x. In other words, Fresenius Medical Care Corporation shares trade at around 16x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Fresenius Medical Care Corporation's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.7971. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Fresenius Medical Care Corporation's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Fresenius Medical Care Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $2.6 billion.
The EBITDA is a measure of a Fresenius Medical Care Corporation's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $18 billion |
|---|---|
| Operating margin TTM | 9.57% |
| Gross profit TTM | $5.1 billion |
| Return on assets TTM | 3.16% |
| Return on equity TTM | 8.12% |
| Profit margin | 4.89% |
| Book value | $22.58 |
| Market capitalisation | $14.7 billion |
TTM: trailing 12 months
Dividend payout ratio: 39.95% of net profits
Recently Fresenius Medical Care Corporation has paid out, on average, around 39.95% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 2.82% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Fresenius Medical Care Corporation shareholders could enjoy a 2.82% return on their shares, in the form of dividend payments. In Fresenius Medical Care Corporation's case, that would currently equate to about $1.35 per share.
While Fresenius Medical Care Corporation's payout ratio might seem fairly standard, it's worth remembering that Fresenius Medical Care Corporation may be investing much of the rest of its net profits in future growth.
Fresenius Medical Care Corporation's most recent dividend payout was on 26 May 2022. The latest dividend was paid out to all shareholders who bought their shares by 12 May 2022 (the "ex-dividend date").
Fresenius Medical Care Corporation's shares were split on a 2:1 basis on 3 December 2012. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Fresenius Medical Care Corporation shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Fresenius Medical Care Corporation shares which in turn could have impacted Fresenius Medical Care Corporation's share price.
Over the last 12 months, Fresenius Medical Care Corporation's shares have ranged in value from as little as $23.29 up to $41.117. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Fresenius Medical Care Corporation's is 0.9427. This would suggest that Fresenius Medical Care Corporation's shares are less volatile than average (for this exchange).
Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company also develops, manufactures, and distributes dialysis products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and systems for water treatment; and non-dialysis products, such as acute cardiopulmonary and apheresis products. In addition, it develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. As of February 23, 2022, it operated 4,171 outpatient dialysis clinics in approximately 150 countries.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.